Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peptide YY 3-36 is a synthetic form of the human gut hormone fragment peptide YY (PYY) comprising amino acids 3 to 36. It is released postprandially from the gastrointestinal tract in proportion to caloric intake and acts as a selective agonist at the neuropeptide Y2 receptor. Its primary mechanism involves reducing appetite and increasing satiety by modulating hypothalamic circuits that regulate energy balance. Peripheral administration of peptide YY 3-36 has been shown to decrease food intake and body weight in both animal models and humans. The compound has been investigated primarily for obesity treatment but also shows potential for metabolic diseases such as diabetes due to its effects on glucose homeostasis[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peptide YY 3-36.